Head-To-Head Survey: LivaNova PLC (LIVN) versus CryoLife (CRY)
CryoLife (NYSE: CRY) and LivaNova PLC (NASDAQ:LIVN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.
This is a breakdown of current ratings and target prices for CryoLife and LivaNova PLC, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
CryoLife presently has a consensus target price of $22.33, indicating a potential upside of 2.21%. LivaNova PLC has a consensus target price of $71.50, indicating a potential upside of 2.38%. Given LivaNova PLC’s higher possible upside, analysts plainly believe LivaNova PLC is more favorable than CryoLife.
This table compares CryoLife and LivaNova PLC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares CryoLife and LivaNova PLC’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|CryoLife||$183.16 million||3.99||$23.56 million||$0.33||66.21|
|LivaNova PLC||$1.21 billion||2.82||$191.69 million||$0.57||122.53|
LivaNova PLC has higher revenue and earnings than CryoLife. CryoLife is trading at a lower price-to-earnings ratio than LivaNova PLC, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
CryoLife has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, LivaNova PLC has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.
Institutional and Insider Ownership
68.4% of CryoLife shares are held by institutional investors. Comparatively, 82.3% of LivaNova PLC shares are held by institutional investors. 6.0% of CryoLife shares are held by company insiders. Comparatively, 0.3% of LivaNova PLC shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
LivaNova PLC beats CryoLife on 8 of the 14 factors compared between the two stocks.
CryoLife, Inc. (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc. valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix. PhotoFix is a pericardial patch stabilized using a dye-mediated photo-fixation process that requires no glutaraldehyde. The Preservation Services segment includes external services, such as preservation of cardiac and vascular tissues. The cardiac and vascular human tissues distributed by CryoLife include the CryoValve SG pulmonary heart valve and the CryoPatch SG pulmonary cardiac patch, both of which are processed using CryoLife’s SynerGraft technology.
About LivaNova PLC
LivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company’s segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products. Cardiac Surgery products include oxygenators, heart-lung machines, autotransfusion, mechanical heart valves and tissue heart valves. The Cardiac Rhythm Management segment is engaged in the development, manufacturing and marketing of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Cardiac Rhythm Management products include high-voltage defibrillators Cardiac Resynchronization Therapy device (CRT-D) and low-voltage pacemakers. The Neuromodulation segment is engaged in the design, development and marketing of neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment resistant depression.
Receive News & Stock Ratings for CryoLife Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife Inc. and related stocks with our FREE daily email newsletter.